Trial Profile
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Regimens Comprising DNA-HIV-PT123, NYVAC-HIV-PT1 and NYVAC-HIV-PT4, and AIDSVAX B/E in Healthy, HIV-Uninfected US and South African Adults
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs DNA HIV PT123 (Primary) ; HIV gp120 vaccine (Primary) ; NYVAC-C (Primary) ; Aluminium hydroxide
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- 22 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 27 Aug 2013 New trial record